Table 2.
Predictive performance of methylation status in individual assays based on urine samples from DRE (n = 87) and FV (n = 67)
| Marker or assay | Sample | #Pos/#Cases | Sensitivity (95% CI) | #Neg/#Controls | Specificity (95% CI) |
|---|---|---|---|---|---|
| ADCY4 | DRE | 23/38 | 0.61 (0.45, 0.74) | 38/49 | 0.78 (0.64, 0.87) |
| FV | 18/32 | 0.56 (0.39, 0.72) | 24/35 | 0.69 (0.52, 0.81) | |
| AOX1rc | DRE | 27/38 | 0.71 (0.55, 0.83) | 34/49 | 0.69 (0.55, 0.80) |
| FV | 14/32 | 0.44 (0.28, 0.61) | 29/35 | 0.83 (0.67, 0.92) | |
| APC2 | DRE | 10/38 | 0.26 (0.15, 0.42) | 44/49 | 0.90 (0.78, 0.96) |
| FV | 4/32 | 0.13 (0.05, 0.28) | 32/35 | 0.91 (0.78, 0.97) | |
| CXCL14 | DRE | 8/38 | 0.21 (0.11, 0.36) | 49/49 | 1.00 (0.93, 1.00) |
| FV | 9/32 | 0.28 (0.16, 0.45) | 34/35 | 0.97 (0.85, 0.99) | |
| CXCL14rc | DRE | 6/38 | 0.16 (0.07, 0.30) | 49/49 | 1.00 (0.93, 1.00) |
| FV | 4/32 | 0.13 (0.05, 0.28) | 35/35 | 1.00 (0.90, 1.00) | |
| CXCL14 Comb. | DRE | 9/38 | 0.24 (0.13, 0.39) | 49/49 | 1.00 (0.93, 1.00) |
| FV | 11/32 | 0.34 (0.20, 0.52) | 34/35 | 0.97 (0.85, 0.99) | |
| EPHX3 | DRE | 25/38 | 0.66 (0.50, 0.79) | 35/49 | 0.71 (0.58, 0.82) |
| FV | 18/32 | 0.56 (0.39, 0.72) | 24/35 | 0.69 (0.52, 0.81) | |
| KIFC2 | DRE | 25/38 | 0.66 (0.50, 0.79) | 38/49 | 0.78 (0.64, 0.87) |
| FV | 18/32 | 0.56 (0.39, 0.72) | 28/35 | 0.80 (0.64, 0.90) | |
| KIFC2rc | DRE | 20/38 | 0.53 (0.37, 0.68) | 42/49 | 0.86 (0.73, 0.93) |
| FV | 11/32 | 0.34 (0.20, 0.52) | 32/35 | 0.91 (0.78, 0.97) | |
| KIFC2 Comb. | DRE | 30/38 | 0.79 (0.64, 0.89) | 34/49 | 0.69 (0.55, 0.80) |
| FV | 21/32 | 0.66 (0.48, 0.80) | 27/35 | 0.77 (0.61, 0.88) | |
| GFRA2 | DRE | 17/38 | 0.45 (0.30, 0.60) | 41/49 | 0.84 (0.71, 0.91) |
| FV | 13/32 | 0.41 (0.26, 0.58) | 29/35 | 0.83 (0.67, 0.92) | |
| GSTP1 | DRE | 18/38 | 0.47 (0.32, 0.63) | 40/49 | 0.82 (0.69, 0.90) |
| FV | 15/32 | 0.47 (0.31, 0.64) | 29/35 | 0.83 (0.67, 0.92) | |
| HEMK1 | DRE | 15/38 | 0.39 (0.26, 0.55) | 46/49 | 0.94 (0.83, 0.98) |
| FV | 8/32 | 0.25 (0.13, 0.42) | 32/35 | 0.91 (0.78, 0.97) | |
| HOXA7 | DRE | 32/38 | 0.84 (0.70, 0.93) | 39/49 | 0.80 (0.66, 0.89) |
| FV | 21/32 | 0.66 (0.48, 0.80) | 23/35 | 0.66 (0.49, 0.79) | |
| HOXB5 | DRE | 29/38 | 0.76 (0.61, 0.87) | 40/49 | 0.82 (0.69, 0.90) |
| FV | 23/32 | 0.72 (0.55, 0.84) | 23/35 | 0.66 (0.49, 0.79) | |
| HOXB5rc | DRE | 27/38 | 0.71 (0.55, 0.83) | 35/49 | 0.71 (0.58, 0.82) |
| FV | 22/32 | 0.69 (0.51, 0.82) | 23/35 | 0.66 (0.49, 0.79) | |
| HOXB5 Comb. | DRE | 32/38 | 0.84 (0.70, 0.93) | 29/49 | 0.59 (0.45, 0.72) |
| FV | 28/32 | 0.88 (0.72, 0.95) | 20/35 | 0.57 (0.41, 0.72) | |
| HOXD3a | DRE | 19/38 | 0.50 (0.35, 0.65) | 45/49 | 0.92 (0.81, 0.97) |
| FV | 15/32 | 0.47 (0.31, 0.64) | 30/35 | 0.86 (0.71, 0.94) | |
| HOXD3b | DRE | 29/38 | 0.76 (0.61, 0.87) | 37/49 | 0.76 (0.62, 0.85) |
| FV | 31/32 | 0.97 (0.84, 0.99) | 21/35 | 0.60 (0.44, 0.74) | |
| HOXD9 | DRE | 26/38 | 0.68 (0.53, 0.81) | 29/49 | 0.59 (0.45, 0.72) |
| FV | 20/32 | 0.63 (0.45, 0.77) | 25/35 | 0.71 (0.55, 0.84) | |
| HOXD10 | DRE | 23/38 | 0.61 (0.45, 0.74) | 42/49 | 0.86 (0.73, 0.93) |
| FV | 17/32 | 0.53 (0.36, 0.69) | 27/35 | 0.77 (0.61, 0.88) | |
| MOXD1 | DRE | 16/38 | 0.42 (0.28, 0.58) | 41/49 | 0.84 (0.71, 0.91) |
| FV | 15/32 | 0.47 (0.31, 0.64) | 32/35 | 0.91 (0.78, 0.97) | |
| NEUROG3 | DRE | 14/38 | 0.37 (0.23, 0.53) | 42/49 | 0.86 (0.73, 0.93) |
| FV | 7/32 | 0.22 (0.11, 0.39) | 33/35 | 0.94 (0.81, 0.98) | |
| NODAL | DRE | 24/38 | 0.63 (0.47, 0.77) | 40/49 | 0.82 (0.69, 0.90) |
| FV | 16/32 | 0.50 (0.34, 0.66) | 28/35 | 0.80 (0.64, 0.90) | |
| NODALrc | DRE | 20/38 | 0.53 (0.37, 0.68) | 41/49 | 0.84 (0.71, 0.91) |
| FV | 10/32 | 0.31 (0.18, 0.49) | 28/35 | 0.80 (0.64, 0.90) | |
| NODAL Comb. | DRE | 30/38 | 0.79 (0.64, 0.89) | 35/49 | 0.71 (0.58, 0.82) |
| FV | 19/32 | 0.59 (0.42, 0.74) | 24/35 | 0.69 (0.52, 0.81) | |
| RASSF5 | DRE | 9/38 | 0.24 (0.13, 0.39) | 46/49 | 0.94 (0.83, 0.98) |
| FV | 9/32 | 0.28 (0.16, 0.45) | 35/35 | 1.00 (0.90, 1.00) | |
| RASSF5rc | DRE | 10/38 | 0.26 (0.15, 0.42) | 43/49 | 0.88 (0.76, 0.94) |
| FV | 11/32 | 0.34 (0.20, 0.52) | 30/35 | 0.86 (0.71, 0.94) | |
| RASSF5 Comb. | DRE | 17/38 | 0.45 (0.30, 0.60) | 40/49 | 0.82 (0.69, 0.90) |
| FV | 19/32 | 0.59 (0.42, 0.74) | 30/35 | 0.86 (0.71, 0.94) |
The estimated sensitivity and specificity of individual assays and combined markers. The column #Pos/#cases shows the number of positive tests from cases and the total number of biopsy positive cases analyzed. Similarly, the column #Pos/#controls yields the number of negative tests from controls and the number of biopsy negative controls
CI confidence interval, rc reverse complement, Comb. combined results as described in the “Results” section